Collagenase Clostridium histolyticum for the Treatment of Peyronie's Disease: The Development of This Novel Pharmacologic Approach

Publisher： John Wiley & Sons Inc

E-ISSN： 1743-6109|12|6|1481-1489

ISSN： 1743-6095

Source： THE JOURNAL OF SEXUAL MEDICINE, Vol.12, Iss.6, 2015-06, pp. : 1481-1489

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PD Surgery Following CCH

By  

THE JOURNAL OF SEXUAL MEDICINE, Vol. 12, Iss. 1, 2015-01 ,pp. : 259-264

John Wiley & Sons Inc

Access to resources Recommend Favorite

CCH Phase 3 Open‐Label Study

By  

THE JOURNAL OF SEXUAL MEDICINE, Vol. 12, Iss. 1, 2015-01 ,pp. : 248-258

John Wiley & Sons Inc

Access to resources Recommend Favorite

Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie's disease (PD)

By  

BJU INTERNATIONAL, Vol. 116, Iss. 5, 2015-11 ,pp. : 815-822

John Wiley & Sons Inc

Access to resources Recommend Favorite

Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie's disease (PD)

By  

BJU INTERNATIONAL, Vol. 1464-4096, Iss. 5, 2015-11 ,pp. : 815-822

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double‐blind, randomized, placebo‐controlled, phase III studies

By  

BJU INTERNATIONAL, Vol. 116, Iss. 4, 2015-10 ,pp. : 650-656

John Wiley & Sons Inc

Access to resources Recommend Favorite